Clinical Trial Update: CAR19BCMA CAR-T Cells for the Treatment of R/R Plasma Cell Neoplasms [EARLY_Phase 1]

View source ↗

Summary

ClinicalTrials.gov entry for an early phase 1 study of CAR19BCMA CAR-T cells for relapsed or refractory plasma cell neoplasms. The trial is not yet recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Plasma Cell Neoplasms

Drugs mentioned

• CAR19BCMA CAR-T cells

Snippet

Sponsor: Chinese PLA General Hospital | Conditions: Relapsed or Refractory Plasma Cell Neoplasms | EARLY_Phase 1 | Status: NOT_YET_RECRUITING